{
  "Record_id": "ARV-DEN-001",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Tetravalent (DENV1-4)",
  "VaccineCandidateName": "Butantan-DV",
  "VaccineStatus": "Registered",
  "Highest Phase": "Registered (Marketed)",
  "Platform": "Recombinant Live-attenuated Vaccine",
  "Lead Developer": "Instituto Butantan",
  "Country": "Brazil",
  "Note": "Single-dose schedule; first single-dose dengue vaccine; ages 12-59 y; WuXi Vaccines manufacturing partner",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-002",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Tetravalent (DENV1-4)",
  "VaccineCandidateName": "Dengvaxia (CYD-TDV)",
  "VaccineStatus": "Registered",
  "Highest Phase": "Registered (Marketed)",
  "Platform": "Recombinant Live-attenuated Vaccine",
  "Lead Developer": "Sanofi Pasteur",
  "Country": "France",
  "Note": "3-dose schedule (0, 6, 12 mo); YF17D backbone; restricted to seropositive individuals (WHO 2018)",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-003",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Tetravalent (DENV1-4)",
  "VaccineCandidateName": "QDENGA (TAK-003 \/ DENVax)",
  "VaccineStatus": "Registered",
  "Highest Phase": "Registered (Marketed)",
  "Platform": "Recombinant Live-attenuated Vaccine",
  "Lead Developer": "Takeda",
  "Country": "Japan",
  "Note": "2-dose schedule (0, 3 mo); DENV-2 PDK-53 backbone (Inviragen origin); EMA-approved 2022",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-004",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Tetravalent (DENV1-4)",
  "VaccineCandidateName": "DengiAll (Panacea Biotec)",
  "VaccineStatus": "Active\/Ongoing",
  "Highest Phase": "Clinical — Phase 3",
  "Platform": "Recombinant Live-attenuated Vaccine",
  "Lead Developer": "Panacea Biotec Limited; Indian Council of Medical Research",
  "Country": "India",
  "Note": "NIH TV003 backbone (licensed); single-dose; Phase 3 active in India",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-005",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Tetravalent (DENV1-4)",
  "VaccineCandidateName": "TDENV-LAV (WRAIR\/GSK)",
  "VaccineStatus": "Completed",
  "Highest Phase": "Clinical — Phase 2",
  "Platform": "Live Attenuated Vaccine",
  "Lead Developer": "Walter Reed Army Institute of Research; GlaxoSmithKline",
  "Country": "USA \/ UK",
  "Note": "Live attenuated; primate cell-derived; WRAIR\/GSK collaboration",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-006",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Tetravalent (DENV1-4)",
  "VaccineCandidateName": "NIH TV003\/TV005 (rDENΔ30 \/ LATV)",
  "VaccineStatus": "Completed",
  "Highest Phase": "Clinical — Phase 2",
  "Platform": "Recombinant Live-attenuated Vaccine",
  "Lead Developer": "National Institute of Allergy and Infectious Diseases (NIAID), NIH",
  "Country": "USA",
  "Note": "rDENΔ30 backbone (3' UTR deletion attenuation); developed by NIAID\/LID; technology source for Butantan-DV, DengiAll, Dengusiil, HBI rDV",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-007",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Tetravalent (DENV1-4)",
  "VaccineCandidateName": "V181 (Merck\/Butantan)",
  "VaccineStatus": "Completed",
  "Highest Phase": "Clinical — Phase 2",
  "Platform": "Recombinant Live-attenuated Vaccine",
  "Lead Developer": "Merck",
  "Country": "USA",
  "Note": "Live attenuated; Merck\/Butantan collaboration",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-008",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Tetravalent (DENV1-4)",
  "VaccineCandidateName": "TDENV-PIV (WRAIR\/GSK)",
  "VaccineStatus": "Completed",
  "Highest Phase": "Clinical — Phase 1\/2",
  "Platform": "Purified Inactivated Vaccine",
  "Lead Developer": "Walter Reed Army Institute of Research; GlaxoSmithKline",
  "Country": "USA \/ UK",
  "Note": "Purified inactivated; alum-adjuvanted; designed for prime-boost regimens",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-009",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Tetravalent (DENV1-4)",
  "VaccineCandidateName": "Dengusiil (Serum Institute of India)",
  "VaccineStatus": "Active\/Ongoing",
  "Highest Phase": "Clinical — Phase 1\/2",
  "Platform": "Recombinant Live-attenuated Vaccine",
  "Lead Developer": "Serum Institute of India",
  "Country": "India",
  "Note": "NIH TV003 backbone (licensed to Serum Institute of India)",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-010",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Tetravalent (DENV1-4)",
  "VaccineCandidateName": "TVDV (NMRC tetravalent DNA)",
  "VaccineStatus": "Completed",
  "Highest Phase": "Clinical — Phase 1",
  "Platform": "DNA Vaccine",
  "Lead Developer": "U.S. Army Medical Research and Development Command",
  "Country": "USA",
  "Note": "DNA vaccine; Vaxfectin adjuvant; NMRC platform",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-011",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Tetravalent (DENV1-4)",
  "VaccineCandidateName": "TDENV-LAV\/PIV Prime-Boost (USAMRMC)",
  "VaccineStatus": "Active\/Ongoing",
  "Highest Phase": "Clinical — Phase 1",
  "Platform": "Homologous Prime-Boost",
  "Lead Developer": "U.S. Army Medical Research and Development Command",
  "Country": "USA",
  "Note": "Heterologous prime-boost regimen combining TDENV-LAV and TDENV-PIV",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-012",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Tetravalent (DENV1-4)",
  "VaccineCandidateName": "KD382 (KM Biologics)",
  "VaccineStatus": "Active\/Ongoing",
  "Highest Phase": "Clinical — Phase 1",
  "Platform": "Live Attenuated Vaccine",
  "Lead Developer": "KM Biologics",
  "Country": "Japan",
  "Note": "Mahidol PDK-derived attenuated strains; KM Biologics development",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-013",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Tetravalent (DENV1-4)",
  "VaccineCandidateName": "CodaVax-DENV (Codagenix)",
  "VaccineStatus": "Active\/Ongoing",
  "Highest Phase": "Clinical — Phase 1",
  "Platform": "Live-attenuated Vaccine",
  "Lead Developer": "Codagenix",
  "Country": "USA",
  "Note": "Codon de-optimized live attenuated platform",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-014",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Multivalent peptide",
  "VaccineCandidateName": "PepGNP-Dengue (Gylden\/Emergex)",
  "VaccineStatus": "Completed",
  "Highest Phase": "Clinical — Phase 1",
  "Platform": "Peptide-based synthetic vaccine",
  "Lead Developer": "Gylden Pharma",
  "Country": "UK",
  "Note": "Gold nanoparticle delivery; CD8 T-cell focused; ID administration",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-015",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Tetravalent (DENV1-4)",
  "VaccineCandidateName": "HBI rDV (Indian Immunologicals)",
  "VaccineStatus": "Completed",
  "Highest Phase": "Clinical — Phase 1",
  "Platform": "Recombinant Live-attenuated Vaccine",
  "Lead Developer": "Human Biologicals Institute, Indian Immunologicals",
  "Country": "India",
  "Note": "Recombinant live attenuated; Indian Immunologicals (HBI) development",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-016",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Monovalent DENV-1",
  "VaccineCandidateName": "DEN-80E (Hawaii Biotech subunit)",
  "VaccineStatus": "Completed",
  "Highest Phase": "Clinical — Phase 1",
  "Platform": "Subunit Vaccine",
  "Lead Developer": "Hawaii Biotech",
  "Country": "USA",
  "Note": "Truncated envelope (80E) recombinant subunit; ISCOMATRIX adjuvant",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-017",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Tetravalent (DENV1-4)",
  "VaccineCandidateName": "V180 (Merck subunit)",
  "VaccineStatus": "Completed",
  "Highest Phase": "Clinical — Phase 1",
  "Platform": "Subunit Vaccine",
  "Lead Developer": "National Institute of Allergy and Infectious Diseases (NIAID), NIH; Merck Sharp & Dohme",
  "Country": "USA",
  "Note": "Recombinant subunit; alum or ISCOMATRIX adjuvant",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-018",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Monovalent or multivalent (varies)",
  "VaccineCandidateName": "DEN-prM-E (preclinical subunit\/DNA)",
  "VaccineStatus": "Completed",
  "Highest Phase": "Preclinical",
  "Platform": "DNA Vaccine",
  "Lead Developer": "Centers for Disease Control and Prevention",
  "Country": "USA",
  "Note": "prM\/E based; DNA or subunit constructs; CDC platform",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-019",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Tetravalent (DENV1-4)",
  "VaccineCandidateName": "SynCon tetravalent DNA (Inovio)",
  "VaccineStatus": "Inactive\/Discontinued",
  "Highest Phase": "Preclinical",
  "Platform": "DNA Vaccine",
  "Lead Developer": "VGX Pharmaceuticals; Inovio Pharmaceuticals",
  "Country": "—",
  "Note": "Consensus DNA antigens; electroporation delivery; Inovio SynCon platform",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-020",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Tetravalent (DENV1-4)",
  "VaccineCandidateName": "Tetravalent prME DNA (Thailand consortium)",
  "VaccineStatus": "Completed",
  "Highest Phase": "Preclinical",
  "Platform": "DNA Vaccine",
  "Lead Developer": "Chula Vaccine Research Center (Chula VRC); Chiang Mai University; National Science and Technology Development Agency (NSTDA)",
  "Country": "Thailand",
  "Note": "prM-E DNA platform; Chula VRC + Chiang Mai University + NSTDA collaboration",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-021",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Monovalent DENV-2",
  "VaccineCandidateName": "YF17D\/PE1D2 prime-boost (Fiocruz)",
  "VaccineStatus": "Completed",
  "Highest Phase": "Preclinical",
  "Platform": "DNA Vaccine",
  "Lead Developer": "Oswaldo Cruz Foundation (Fiocruz)",
  "Country": "Brazil",
  "Note": "Heterologous prime-boost; YF17D-DEN2 chimeric prime + PE1D2 DNA boost",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-022",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Monovalent DENV-2",
  "VaccineCandidateName": "ChinDENV (China)",
  "VaccineStatus": "Completed",
  "Highest Phase": "Preclinical",
  "Platform": "Live Attenuated Vaccine",
  "Lead Developer": "Beijing Institute of Microbiology and Epidemiology; Chengdu Institute of Biological Products",
  "Country": "China",
  "Note": "Live attenuated; Beijing Institute of Microbiology and Epidemiology + Chengdu Institute of Biological Products",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-023",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Monovalent DENV",
  "VaccineCandidateName": "DEN 2-O-methyltransferase mutant",
  "VaccineStatus": "Completed",
  "Highest Phase": "Preclinical",
  "Platform": "Live Attenuated Vaccine",
  "Lead Developer": "Novartis Institute for Tropical Diseases; Agency for Science, Technology and Research",
  "Country": "—",
  "Note": "2'-O-methyltransferase attenuation strategy; Novartis\/A*STAR collaboration",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-024",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Tetravalent (DENV1-4)",
  "VaccineCandidateName": "DEN\/DEN chimeric",
  "VaccineStatus": "Completed",
  "Highest Phase": "Preclinical",
  "Platform": "Live Attenuated Vaccine",
  "Lead Developer": "Chiang Mai University; Institute of Molecular Biosciences, Mahidol University; National Science and Technology Development Agency (NSTDA); BioNet-Asia",
  "Country": "Thailand",
  "Note": "DEN\/DEN chimeric construct; Thailand consortium",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-025",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Live attenuated (variable)",
  "VaccineCandidateName": "Dengue HR mutation (Arbovax)",
  "VaccineStatus": "Inactive\/Discontinued",
  "Highest Phase": "Preclinical",
  "Platform": "Live Attenuated Vaccine",
  "Lead Developer": "Arbovax",
  "Country": "USA",
  "Note": "Host-range restricted mutation strategy; Arbovax development",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-026",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Monovalent DENV-1",
  "VaccineCandidateName": "Psoralen-inactivated DENV (NMRC)",
  "VaccineStatus": "Completed",
  "Highest Phase": "Preclinical",
  "Platform": "Purified Inactivated Vaccine",
  "Lead Developer": "Naval Medical Research Center (NMRC)",
  "Country": "USA",
  "Note": "Psoralen photochemical inactivation; NMRC platform",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-027",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Variable (DEN antigens)",
  "VaccineCandidateName": "VEE-Dengue VRPs",
  "VaccineStatus": "Completed",
  "Highest Phase": "Preclinical",
  "Platform": "Purified Inactivated Vaccine",
  "Lead Developer": "Global Vaccines",
  "Country": "—",
  "Note": "VEE replicon particles expressing DEN antigens",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-028",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Consensus (cross-serotype)",
  "VaccineCandidateName": "Consensus EDIII (cED III)",
  "VaccineStatus": "Completed",
  "Highest Phase": "Preclinical",
  "Platform": "Subunit Vaccine",
  "Lead Developer": "National Health Research Institutes (NHRI)",
  "Country": "Taiwan",
  "Note": "Consensus envelope domain III subunit; NHRI Taiwan",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-029",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Variable (EDIII antigens)",
  "VaccineCandidateName": "DENV-EDIII (CIGB Cuba)",
  "VaccineStatus": "Completed",
  "Highest Phase": "Preclinical",
  "Platform": "Subunit Vaccine",
  "Lead Developer": "Center for Genetic Engineering and Biotechnology (CIGB)",
  "Country": "Cuba",
  "Note": "Envelope domain III recombinant subunit; CIGB Cuba",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-030",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Variable (E antigens)",
  "VaccineCandidateName": "Flagellin-E fusion (Vaxinnate)",
  "VaccineStatus": "Inactive\/Discontinued",
  "Highest Phase": "Preclinical",
  "Platform": "Subunit Vaccine",
  "Lead Developer": "Vaxinnate",
  "Country": "USA",
  "Note": "Flagellin-envelope fusion; TLR5 agonist self-adjuvanted",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-031",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Variable (DEN antigens)",
  "VaccineCandidateName": "MV-DEN (Themis\/Pasteur)",
  "VaccineStatus": "Inactive\/Discontinued",
  "Highest Phase": "Preclinical",
  "Platform": "Viral Vector Vaccine",
  "Lead Developer": "Themis Bioscience; Institut Pasteur",
  "Country": "Austria",
  "Note": "Measles vector expressing DEN antigens; Themis\/Pasteur platform",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-032",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Tetravalent (DENV1-4)",
  "VaccineCandidateName": "CAdVax-DenTV",
  "VaccineStatus": "Completed",
  "Highest Phase": "Preclinical",
  "Platform": "Viral vector vaccine",
  "Lead Developer": "Naval Medical Research Center; GenPhar",
  "Country": "USA",
  "Note": "Complex adenovirus vector platform; NMRC\/GenPhar",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-033",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Monovalent DENV-2",
  "VaccineCandidateName": "DENV-2 VLPs",
  "VaccineStatus": "Completed",
  "Highest Phase": "Preclinical",
  "Platform": "Virus Like Particles Vaccine (VLPs) ",
  "Lead Developer": "Chiang Mai University; Institute of Molecular Biosciences, Mahidol University; National Science and Technology Development Agency (NSTDA)",
  "Country": "Thailand",
  "Note": "Virus-like particles; Thailand consortium (Mahidol\/CMU\/NSTDA)",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-034",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Tetravalent (DENV1-4)",
  "VaccineCandidateName": "DSV4 (ICGEB India VLP)",
  "VaccineStatus": "Completed",
  "Highest Phase": "Preclinical",
  "Platform": "Virus Like Particles Vaccine (VLPs) ",
  "Lead Developer": "International Centre for Genetic Engineering and Biotechnology (ICGEB)",
  "Country": "—",
  "Note": "Virus-like particles; ICGEB India",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-DEN-035",
  "Vaccine": "Dengue Vaccine",
  "VaccineSub": "Tetravalent (DENV1-4)",
  "VaccineCandidateName": "AM-DV-01",
  "VaccineStatus": "Active\/Ongoing",
  "Highest Phase": "Preclinical",
  "Platform": "mRNA Vaccine",
  "Lead Developer": "AcadeMab Biomedical; Academia Sinica",
  "Country": "—",
  "Note": "mRNA-based; AcadeMab Biomedical\/Academia Sinica development",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-ZIK-001",
  "Vaccine": "Zika Vaccine",
  "VaccineSub": "Monovalent ZIKV",
  "VaccineCandidateName": "VRC5283 (NIAID\/VRC)",
  "VaccineStatus": "Completed",
  "Highest Phase": "Clinical — Phase 2",
  "Platform": "DNA vaccine",
  "Lead Developer": "Vaccine Research Center (VRC), NIAID\/NIH",
  "Country": "United States of America",
  "Note": "Wild-type ZIKV prM\/E from H\/PF\/2013 strain; needle-free injection; Phase 2 efficacy trial NCT03110770; most advanced DNA candidate",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-ZIK-002",
  "Vaccine": "Zika Vaccine",
  "VaccineSub": "Monovalent ZIKV",
  "VaccineCandidateName": "mRNA-1893 (Moderna)",
  "VaccineStatus": "Active\/Ongoing",
  "Highest Phase": "Clinical — Phase 2",
  "Platform": "mRNA vaccine",
  "Lead Developer": "Moderna",
  "Country": "United States of America",
  "Note": "mRNA encoding prM\/E (Asian strain Micronesia 2007); LNP delivery; FDA Fast Track; Phase 2 NCT04917861 (n=809) data collection completed mid-2024; results pending; most advanced Zika vaccine candidate globally",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-ZIK-003",
  "Vaccine": "Zika Vaccine",
  "VaccineSub": "Monovalent ZIKV",
  "VaccineCandidateName": "GLS-5700 \/ ZIKV-prME (Inovio\/GeneOne)",
  "VaccineStatus": "Inactive\/Discontinued",
  "Highest Phase": "Clinical — Phase 1",
  "Platform": "DNA vaccine",
  "Lead Developer": "GeneOne Life Science; Inovio Pharmaceuticals",
  "Country": "South Korea \/ USA",
  "Note": "Synthetic DNA encoding ZIKV prM\/E; electroporation delivery; Phase 1 completed with strong immunogenicity; Inovio shifted focus away from Zika",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-ZIK-004",
  "Vaccine": "Zika Vaccine",
  "VaccineSub": "Monovalent ZIKV",
  "VaccineCandidateName": "VRC5288 (NIAID\/VRC)",
  "VaccineStatus": "Inactive\/Discontinued",
  "Highest Phase": "Clinical — Phase 1",
  "Platform": "DNA vaccine (ZIKV\/JEV chimera)",
  "Lead Developer": "Vaccine Research Center (VRC), NIAID\/NIH",
  "Country": "United States of America",
  "Note": "ZIKV\/JEV chimera (E protein stem-anchor swapped to JEV); Phase 1 completed; superseded by VRC5283",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-ZIK-005",
  "Vaccine": "Zika Vaccine",
  "VaccineSub": "Monovalent ZIKV",
  "VaccineCandidateName": "BBV121 (Bharat Biotech)",
  "VaccineStatus": "Inactive\/Discontinued",
  "Highest Phase": "Clinical — Phase 1",
  "Platform": "Inactivated whole virus vaccine",
  "Lead Developer": "Bharat Biotech",
  "Country": "India",
  "Note": "Inactivated; Phase 1 completed; no public update since 2018-2019; Bharat Biotech focus shifted to other vaccines",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-ZIK-006",
  "Vaccine": "Zika Vaccine",
  "VaccineSub": "Monovalent ZIKV",
  "VaccineCandidateName": "PIZV \/ TAK-426 (Takeda)",
  "VaccineStatus": "Completed",
  "Highest Phase": "Clinical — Phase 1",
  "Platform": "Inactivated whole virus vaccine",
  "Lead Developer": "Takeda",
  "Country": "Japan",
  "Note": "Purified inactivated Zika; alum-adjuvanted; 10 µg dose selected; 2-year safety\/immunogenicity follow-up published 2023; Phase 2 not yet initiated",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-ZIK-007",
  "Vaccine": "Zika Vaccine",
  "VaccineSub": "Monovalent ZIKV",
  "VaccineCandidateName": "VLA1601 (Valneva\/Emergent)",
  "VaccineStatus": "Inactive\/Discontinued",
  "Highest Phase": "Clinical — Phase 1",
  "Platform": "Inactivated whole virus vaccine",
  "Lead Developer": "Valneva Austria GmbH; Emergent BioSolutions",
  "Country": "Austria \/ USA",
  "Note": "Inactivated; alum-adjuvanted; Phase 1 completed in 2018-2019; Valneva and Emergent paused development",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-ZIK-008",
  "Vaccine": "Zika Vaccine",
  "VaccineSub": "Monovalent ZIKV",
  "VaccineCandidateName": "ZPIV (BIDMC\/NIAID\/WRAIR)",
  "VaccineStatus": "Completed",
  "Highest Phase": "Clinical — Phase 1",
  "Platform": "Inactivated whole virus vaccine",
  "Lead Developer": "Beth Israel Deaconess Medical Center (BIDMC); NIAID; WRAIR",
  "Country": "United States of America",
  "Note": "Strain PRVABC59 (Puerto Rico isolate); formalin-inactivated; alum-adjuvanted; 4 Phase 1 trials completed; preferred for pregnant women due to safety profile; technology transferred to Takeda for TAK-426",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-ZIK-009",
  "Vaccine": "Zika Vaccine",
  "VaccineSub": "Monovalent ZIKV",
  "VaccineCandidateName": "rZIKV\/D4Δ30-713 (NIAID)",
  "VaccineStatus": "Completed",
  "Highest Phase": "Clinical — Phase 1",
  "Platform": "Live-attenuated chimeric (DENV4 backbone)",
  "Lead Developer": "National Institute of Allergy and Infectious Disease (NIAID), NIH",
  "Country": "United States of America",
  "Note": "Live attenuated chimeric expressing ZIKV prM\/E in rDEN4Δ30 backbone; Phase 1 completed; NIAID\/LID",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-ZIK-010",
  "Vaccine": "Zika Vaccine",
  "VaccineSub": "Monovalent ZIKV",
  "VaccineCandidateName": "Ad26.ZIKV.001 (Janssen)",
  "VaccineStatus": "Completed",
  "Highest Phase": "Clinical — Phase 1",
  "Platform": "Recombinant viral vector (Ad26)",
  "Lead Developer": "Janssen Vaccines",
  "Country": "Netherlands",
  "Note": "Replication-incompetent Ad26 vector; Janssen Vaccines & Prevention; Phase 1 completed",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-ZIK-011",
  "Vaccine": "Zika Vaccine",
  "VaccineSub": "Monovalent ZIKV",
  "VaccineCandidateName": "ChAdOx1 Zika (Oxford)",
  "VaccineStatus": "Completed",
  "Highest Phase": "Clinical — Phase 1",
  "Platform": "Recombinant viral vector (Chimp adenovirus)",
  "Lead Developer": "University of Oxford",
  "Country": "United Kingdom",
  "Note": "ChAdOx1 chimpanzee adenovirus vector; Phase 1 trial; Oxford Jenner Institute",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-ZIK-012",
  "Vaccine": "Zika Vaccine",
  "VaccineSub": "Monovalent ZIKV",
  "VaccineCandidateName": "MV-ZIKV (Themis Bioscience)",
  "VaccineStatus": "Inactive\/Discontinued",
  "Highest Phase": "Clinical — Phase 1",
  "Platform": "Recombinant viral vector (Measles)",
  "Lead Developer": "Themis Bioscience GmbH",
  "Country": "Austria",
  "Note": "Measles vector; includes both MV-ZIKV and MV-ZIKV-RSP variants; Themis acquired by Merck in 2020 — Zika program not actively continued",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-ZIK-013",
  "Vaccine": "Zika Vaccine",
  "VaccineSub": "Monovalent ZIKV (NS1-based)",
  "VaccineCandidateName": "pVAX-tpaNS1 (U. Adelaide)",
  "VaccineStatus": "Active\/Ongoing",
  "Highest Phase": "Preclinical",
  "Platform": "DNA vaccine",
  "Lead Developer": "University of Adelaide",
  "Country": "Australia",
  "Note": "NS1 DNA antigen; tPA leader sequence; HD-MAP (high-density microarray patch) delivery; thermostable (40°C\/28d); University of Adelaide; AUD 1.35M funding",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-ZIK-014",
  "Vaccine": "Zika Vaccine",
  "VaccineSub": "Monovalent ZIKV",
  "VaccineCandidateName": "GMZ-002 PIV (Vero-adapted)",
  "VaccineStatus": "Active\/Ongoing",
  "Highest Phase": "Preclinical",
  "Platform": "Inactivated whole virus vaccine",
  "Lead Developer": "Academic consortium",
  "Country": "China",
  "Note": "Vero cell-adapted ZIKV strain (GMZ-002); purified inactivated; high productivity in Vero cells; full protection in IFNAR1-blocked mouse model",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-ZIK-015",
  "Vaccine": "Zika Vaccine",
  "VaccineSub": "Monovalent ZIKV",
  "VaccineCandidateName": "Butantan Zika vaccine",
  "VaccineStatus": "Active\/Ongoing",
  "Highest Phase": "Preclinical",
  "Platform": "Live attenuated vaccine",
  "Lead Developer": "Instituto Butantan",
  "Country": "Brazil",
  "Note": "Brazilian Instituto Butantan Zika program; animal testing started 2H 2024; leverages dengue platform expertise",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-ZIK-016",
  "Vaccine": "Zika Vaccine",
  "VaccineSub": "Monovalent ZIKV",
  "VaccineCandidateName": "iosBio OraPro-Zika",
  "VaccineStatus": "Active\/Ongoing",
  "Highest Phase": "Preclinical",
  "Platform": "Recombinant viral vector (Adenovirus type 5, oral)",
  "Lead Developer": "iosBio",
  "Country": "United Kingdom",
  "Note": "Orally administered AdHu5 (E1\/E3 deleted) vector; iosBio OraPro thermostable platform",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-ZIK-017",
  "Vaccine": "Zika Vaccine",
  "VaccineSub": "Monovalent ZIKV (NS1-based)",
  "VaccineCandidateName": "GEO-ZM02 (GeoVax)",
  "VaccineStatus": "Active\/Ongoing",
  "Highest Phase": "Preclinical",
  "Platform": "Recombinant viral vector (Modified vaccinia Ankara)",
  "Lead Developer": "GeoVax Labs",
  "Country": "United States of America",
  "Note": "MVA vector expressing ZIKV NS1; NS1 antigen avoids antibody-dependent enhancement (ADE); single-dose 100% protection in preclinical lethal challenge",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-CHK-001",
  "Vaccine": "Chikungunya Vaccine",
  "VaccineSub": "Monovalent CHIKV",
  "VaccineCandidateName": "IXCHIQ (VLA1553)",
  "VaccineStatus": "Registered",
  "Highest Phase": "Registered (Marketed)",
  "Platform": "Live-attenuated vaccine",
  "Lead Developer": "Valneva",
  "Country": "Austria \/ France",
  "Note": "World's first chikungunya vaccine; FDA approved Nov 2023 (accelerated pathway); EMA approved Jun 2024; Health Canada and UK MHRA also approved; Brazil ANVISA under review; single IM dose; ages 18+ (12+ in EU); 98.5% seroresponse at day 28; live attenuated Δ5nsP3 deletion; produced via Vero cells; CEPI-funded; pediatric trial NCT06106581 ongoing (1-11 y); efficacy data expected 2029; ⚠️ severe AE reports in ≥65 y led to restricted use in elderly in Canada\/Germany\/France\/UK",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-CHK-002",
  "Vaccine": "Chikungunya Vaccine",
  "VaccineSub": "Monovalent CHIKV",
  "VaccineCandidateName": "VIMKUNYA (PXVX0317)",
  "VaccineStatus": "Registered",
  "Highest Phase": "Registered (Marketed)",
  "Platform": "Virus-like particles vaccine (VLPs)",
  "Lead Developer": "Bavarian Nordic",
  "Country": "Denmark",
  "Note": "Acquired from Emergent BioSolutions (originally PaxVax); FDA approved 14 Feb 2025; EC approval 28 Feb 2025; ages 12+; VLPs from CHIKV Senegal strain 37997 (C, E1, E2 proteins) expressed in HEK cells; alum-adjuvanted; single IM dose; pre-filled syringe; 3-year shelf life; ~95% seroresponse short-term; PRIME (2019), Fast Track (2018), Breakthrough (2020); >12,500 doses administered post-authorization (US+Germany) by Aug 2025; favorable safety in ≥65 y (no SAE) — preferred over Ixchiq for elderly",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-CHK-003",
  "Vaccine": "Chikungunya Vaccine",
  "VaccineSub": "Monovalent CHIKV",
  "VaccineCandidateName": "BBV87 (Bharat Biotech)",
  "VaccineStatus": "Active\/Ongoing",
  "Highest Phase": "Clinical — Phase 3",
  "Platform": "Inactivated whole virus vaccine",
  "Lead Developer": "Bharat Biotech International Ltd; International Vaccine Institute (IVI)",
  "Country": "India",
  "Note": "Inactivated whole virion ECSA genotype; alum-adjuvanted; 2-dose IM regimen; CEPI-funded ($14.1M); Phase 2\/3 seamless design across 5 countries (Costa Rica, Panama, Colombia, Guatemala, Thailand) n=3210; SEC India approved Phase 3 in 2025; positioned as low-cost option for endemic LMICs; safety profile suitable for immunocompromised and pregnant women",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-CHK-004",
  "Vaccine": "Chikungunya Vaccine",
  "VaccineSub": "Monovalent CHIKV",
  "VaccineCandidateName": "MV-CHIK (Themis\/Merck)",
  "VaccineStatus": "Inactive\/Discontinued",
  "Highest Phase": "Clinical — Phase 2",
  "Platform": "Recombinant viral vector (Measles)",
  "Lead Developer": "Themis Bioscience (acquired by Merck 2020)",
  "Country": "Austria",
  "Note": "Measles-vectored CHIKV vaccine; Pasteur Institute platform license; Phase 2 published in Lancet 2018 (n=263, 50-100% seroconversion); pre-existing measles immunity didn't affect immunogenicity; Themis acquired by Merck for $366M in 2020; development de-prioritized after Valneva's IXCHIQ approval; no Phase 3 announced",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-CHK-005",
  "Vaccine": "Chikungunya Vaccine",
  "VaccineSub": "Monovalent CHIKV",
  "VaccineCandidateName": "VLA-181388 (Valneva mRNA)",
  "VaccineStatus": "Active\/Ongoing",
  "Highest Phase": "Clinical — Phase 1",
  "Platform": "mRNA vaccine",
  "Lead Developer": "Valneva",
  "Country": "Austria \/ France",
  "Note": "Valneva's second-generation chikungunya vaccine using mRNA platform; Phase 1 trial; complementary strategy to IXCHIQ for populations unsuitable for live-attenuated vaccine (immunocompromised, elderly with safety concerns, pregnant women)",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-CHK-006",
  "Vaccine": "Chikungunya Vaccine",
  "VaccineSub": "Monovalent CHIKV",
  "VaccineCandidateName": "mRNA-1944 (Moderna)",
  "VaccineStatus": "Inactive\/Discontinued",
  "Highest Phase": "Clinical — Phase 1",
  "Platform": "mRNA vaccine (passive antibody)",
  "Lead Developer": "Moderna",
  "Country": "United States of America",
  "Note": "⚠️ Not a traditional vaccine — encodes a fully human IgG monoclonal antibody (CHKV-24) for passive immunoprophylaxis; isolated from B cells of CHIKV convalescent patient; Phase 1 completed; Moderna shifted focus to other targets after CHIKV vaccine market dominated by Valneva\/Bavarian Nordic",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-CHK-007",
  "Vaccine": "Chikungunya Vaccine",
  "VaccineSub": "Monovalent CHIKV",
  "VaccineCandidateName": "CHIKV DNA (synthetic-encoded antibody)",
  "VaccineStatus": "Active\/Ongoing",
  "Highest Phase": "Preclinical",
  "Platform": "DNA vaccine (DMAb)",
  "Lead Developer": "Wistar Institute; Inovio Pharmaceuticals",
  "Country": "United States of America",
  "Note": "DNA-encoded monoclonal antibody (DMAb) platform; in vivo expression of neutralizing antibody; preclinical proof-of-concept in mice and NHPs",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-CHK-008",
  "Vaccine": "Chikungunya Vaccine",
  "VaccineSub": "Monovalent CHIKV",
  "VaccineCandidateName": "CHIKV\/IRES (Inactivated)",
  "VaccineStatus": "Active\/Ongoing",
  "Highest Phase": "Preclinical",
  "Platform": "Live-attenuated vaccine (IRES-attenuated)",
  "Lead Developer": "University of Texas Medical Branch (UTMB); Takeda",
  "Country": "United States of America",
  "Note": "Internal ribosome entry site (IRES) attenuation strategy; alternative attenuation mechanism to VLA1553; preclinical immunogenic in NHPs",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-CHK-009",
  "Vaccine": "Chikungunya Vaccine",
  "VaccineSub": "Monovalent CHIKV",
  "VaccineCandidateName": "CD8 T-cell CHIKV adaptive vaccine",
  "VaccineStatus": "Active\/Ongoing",
  "Highest Phase": "Preclinical",
  "Platform": "Peptide-based \/ T-cell vaccine",
  "Lead Developer": "Academic consortium",
  "Country": "Various",
  "Note": "Novel CD8+ T cell-focused vaccine; Mar 2025 publication in mouse and rhesus macaque models; potential complement to antibody-based vaccines for chronic arthritis prevention",
  "CreateDate": "2026-04-13"
 },
 {
  "Record_id": "ARV-CHK-010",
  "Vaccine": "Chikungunya Vaccine",
  "VaccineSub": "Monovalent CHIKV",
  "VaccineCandidateName": "saRNA Chikungunya (CureVac)",
  "VaccineStatus": "Active\/Ongoing",
  "Highest Phase": "Preclinical",
  "Platform": "self-amplifying mRNA vaccine",
  "Lead Developer": "Various academic groups",
  "Country": "Various",
  "Note": "Self-amplifying RNA platform; lower dose, longer expression; multiple academic groups exploring; preclinical proof-of-concept demonstrated",
  "CreateDate": "2026-04-13"
 }